The development of molecular diagnostics that detect both the presence of Mycobacterium tuberculosis in clinical samples and drug resistance-conferring mutations promises to revolutionize patient care and interrupt transmission by ensuring early diagnosis. However, these tools require the identification of genetic determinants of resistance to the full range of antituberculosis drugs.
Submitted by Vitor Silverio Rodrigues (vitorsrodrigues@reitoria.unesp.br) on 2014-05-27T11:23:36Z No. of bitstreams: 0Bitstream added on 2014-05-27T14:30:07Z : No. of bitstreams: 1 2-s2.0-45849084706.pdf: 56577 bytes, checksum: 05aec86200a65b32ec8565684534d283 (MD5); Made available in DSpace on 2014-05-27T11:23:36Z (GMT). No. of bitstreams: 0 Previous issue date: 2008-07-02; To highlight the transmission and ma...